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Interleukin-S (IL-S) is a potent pro-inflammatory 
molecule present in high amounts in psoriatic skin. 
Here it may play an important role in the keratinocyte 
hyperproliferation and the neutrophil and T -lympho-
cyte infiltration associated with the disease. In this 
study the effect of protein kinase C inhibitors on IL-S 
production by human keratinocytes in vitro was inves-
tigated. The anti-inflammatory and immunomodula-
tory compound auranofin ([l-thio-beta-D-glucopyr-
anose-2,3,4,6-tetraacetato-S] [triethylphosphine] gold) 
is known to inhibit protein kinase C . In addition, aur-
anofin has been shown to inhibit skin inflammation. 
As such, auranofin was also studied for its effect on IL-S 
I nterleukin-8 (IL-8) is a potent pro-inflammatory polypep-tide composed of 72 amino acids with a molecular weight of approximately 8 kDa [1 ]. Exogenous stimuli such as lipo-polysaccharide (LPS), phorbol myristate acetate (PMA) , tumor necrosis factor-a (TNFa), and interIeukin-lp (IL-IP), 
will induce the production of this molecule in a variety of cell s 
including monocytes, endothelial cells, and keratinocytes [2-8] . 
IL-8 acts as a chemotactic and activation factor for both neutrophils 
and T lymphocytes [2,9]. Stimulation of neutrophils with IL-8 is 
reported to result in degranulation and enzyme release in the pres-
ence of cytochalasin B [10,11 J, increased adherence to unstimulated 
endothelial cells [12], and the production and release ofleukotriene 
B4 (LTB4) and 5-hydroxyeicosatetraenoic acid (5-HETE) [13,14]. 
In addition, IL-8 has been reported to induce the proliferation of 
human keratinocytes irl vitro [15,16] . 
Cytokines are believed to play an iJDportant role in many inflam-
matory diseases of the skin. Recently, a role for IL-8 in dermatologic 
inflammation, particularl y in psoriasis, has been suggested. Psoriasis 
is characterized by keratinocyte hyperproliferation and the accumu-
lation of T lymphocytes and neutrophils in the epidermis. These 
hallmarks may be mediated by the activities of IL-8. In support of 
this, prodigious amounts ofIL-8 were measured in scales taken from 
psoriatic lesions but not in uninvolved psoriatic and non-psoriatic 
skin [6,17 -21]. In addition, high levels ofIL-8 mRNA were dem-
onstrated in psoriatic lesions using ill situ hybridization [6,22] . 
These studies suggest that IL-8 levels are not only elevated in psori-
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production. Auranofin and staurosporine, inhibitors 
of protein kinase C, inhibited phorbol-myristate-
acetate-stimulated IL-S production. Northern analy-
sis of IL-S mRNA revealed that the inhibition of IL-S 
production was associated with an inhibition of IL-S 
mRNA expression. In contrast, these compounds po-
tentiated the minimal IL-S protein and mRNA seen in 
response to interleukin-lp or tumor necrosis factor-a:. 
These findings suggest that IL-S synthesis may be ei-
ther positively or negatively regulated by protein ki-
nase C depending on the stimulus. Key words: aurano-
.fin / interleukin-1 / phorbol ester / IL-8 mRNA. ] Invest 
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atic skin but that keratinocytes i'l situ are capable of synthesizing 
IL-8. 
Interleukin-8 is not found in normal skin, nor is it constitutively 
expressed in unstimulated keratinocytes grown in tissue culture. 
However, stimulation of human keratinocytes ill vitro with IL-IP, 
TNF-a, or the phorbol ester PMA results in a rapid increase in IL-8 
mRNA levels [6-8] and the appearance oflL-8 protein in the cul-
ture supernatants of TNFa-stimulated keratinocytes has been re-
ported [7]. In light of the potential role ofIL-8 in inflammatory skin 
diseases, an understanding of the regulation of its production may 
provide some information valuable in their treatment. 
Recently, protein kinase C inhibitors have been shown to modu-
late a variety ofIL-1P - and PMA-stimulated events [23,24]. In light 
of these findings, the ability of protein kinase C (PKC) inhibitors to 
modulate IL-8 expression was investigated. Included in the com-
pounds tested was auranofin ([1-thio-P-D-glucopyranose-2,3,4,6-
tetraacetato-S] [triethylphosphine] gold). This compound has been 
shown to possess various immunomodulatory and anti-inflanuna-
tory properties [25 ,26] and is able to inhibit protein kinase C [27]. 
Inhibition of protein kinase C was found to modulate IL-8 produc-
tion in keratinocytes stimulated with PMA or IL-lp. Our findings 
suggest that IL-8 synthesis may be regulated either positively or 
negatively by protein kinase C, depending on the stimulus. 
MATERIALS AND METHODS 
Compounds and Reagents Auranoftn (SK&F D-39162), triethylphos-
phine oxide, and 2,3,4,6-tetra-O-acetyl-t-fJ-thioethyl-O-glycoside were 
obtained from the Drug Substances and Products Registry of SmithKline 
Beecham Laboratories (King of Prussia, P A). Sodium aurothiomalate was 
purchased from Aldrich Chemical Co. (Milwaukee, WI). PMA and stauro-
sporine were purchased from Sigma Chemical Co. (St. Louis, MO), H-7 
from Biomol (Plymouth Meeting. PAl, and chelerythrine from L C Services 
(Wobum, MA). IL-lP and TNFa were prepared at Smitl,K1ine Beecham 
Pharmaceuticals (King of Prussia, PAl as described previously [28,29]. 
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Cell Culture Human foreskin keratinocytes were purchased from Clon-
etics Corp. (San Diego, CAl and grown as a monolayer in 24-well tissue 
culture plates at 37"C, 5% CO2 in 1 ml of keratinocyte growth medium (KGM) (Clonetics Corp., San Diego, CAl. These cultures are free of con-
taminating fibroblasts and melanocytes. KGM is based on the MCDB 153 
formulation supplemented with epidermal growth factor (0.1 ngj ml), hy-
drocortisone (0.5 /lgj mI), insulin (5.0 /lgj ml), gentamicin (50 /lgj ml), 
amphotericin-B (50 ngj ml), and bovine pituitary extract. Second-passage 
cultures were used on reaching 80-90% confluency, at which point they 
contained approximately 1 X 105 cells per well. 
Interleukin-8 Production from Human Keratinocytes in Vitro In 
preliminary experiments, keratinocytes were either incubated in 1 ml of 
KGM containing various concentrations ofPMA or IL-lP as indicated, or at 
a given concentration of the stimulant for various lengths of time at 37°C. In 
subsequent studies, the cells were incubated in KGM alone, or with the 
addition of drug just prior to stimulation with PMA (0.1 /lM) or IL-lP 
(1.0 ngj ml) unless indicated. Compounds and PMA were dissolved in di-
methyl sulfoxide (OMSO) and added to the samples such that the final 
concentration ofDMSO did not exceed 0.2%. IL-lpwas dissolved in KGM. 
After 18 h incubation the supernatants were collected and stored frozen until 
assayed for IL-8 content. Interleukin-8 in the culture supernatants was de-
termined using an IL-8 immunoassay kit purchased from R&D Systems 
(Minneapolis, MN) following the manufacturer's instructions. 
Northern Blot Analysis of Interleukin-8 mRNA Production The 
effect of PMA or IL-lP on keratinocyte IL-8 mRNA levels was determined 
by Northern blot analysis . Briefly, keratinocyte monolayers were grown in 
175-cm2 flasks until reaching 90% confluence as described above. The cells 
were stimulated with either PMA (0.1 JiM) for 3 h or IL-lP (1.0 ngjml) for 
1 h in the presence or absence of drug. RNA was prepared using the guanidi-
nium thiocyanate-cesium ch loride cushion method described before [30]. 
RNA was electrophoresed through a 1 % formaldehyde agarose gel and 
blotted onto 0.2-/lm nitrocellulose (Schleicher & Schuell, Keene, NH) ac-
cording to established methods [30]. The blot was prehybridized in 50% 
formamide, 5 X Denhardt's buffer [50 X = 5 g Ficoll (Type 400, Pharma-
cia), 5 g polyvinylpyrro lidone,S g bovine serum albumin (Pentex Fraction 
V) in 500 ml H20], 5 X SSPE, and 100 mgj ml denatured salmon sperm 
DNA for 2-4 h at 42°C. The blot was then hybridized overnight to the 
alkali-denatured IL-8 eDNA probe in the same solution containing 10% 
dextran (wjv) . The filters were washed twice at room temperature in 2 X 
SSPEjO.l % sodium dodecylsulfate (SDS) (1 X SSPE = 150 mM NaCI, 
2 mM Na H2PO., 1 mM ethylenediaminetetraacetic acid [EDTA]) fol-
lowed by washes in 1 X SSPEand 0.5 X SSPEat 50°C and autoradiography. 
After autoradiography, the blot was stripped of radioactive probe by boiling 
in H20 and rehybridized as above with a cyclophillin eDNA probe. The 
IL-8 probe was a synthetic DNA purchased from R&D Systems and isolated 
from the vector by digestion with BamHI and EcoR!, fo llowed by agarose 
gel purification. The cyclophilin eDNA fragment has been previously de-
scribed .[31]. Both fragments were labeled with a-32P-dCTP using a random 
priming kit from Strata gene (La Jolla, CAl and purified through a Stratagene 
push column. Northern blots were quantitated by densitometry as described 
previously [31]. 
RESULTS 
Interleukin-8 Production in Human Keratinocytes Exogen-
ous stimuli such as PMA and IL-lP will induce the production of 
IL-8 in a variety of cells including monocytes and endothelial cells. 
Stimulation of human keratinocytes it! IIitro with PMA resulted in a 
dose-dependent production of IL-8 that was maximal at 0.1 11M 
(Fig 1A). Interleukin-lp also stimulated the production of IL-8, 
with maximal stimulation observed at approximately 1.0 ngj ml 
(Fig lB) . However, the extent of IL-8 production in response to 
this cytokine proved to be much less than it was in response to the 
phorbol ester PMA. That is, PMA consistently resulted in the pro-
duction of 4 - 6 times as much IL-8 in the culture fluid as did stimu-
lation with IL-lp. 
The release of IL-8 into the culture supernatant was time depen-
dent, increasing with time up to 48 h for both stimuli as well as for 
stimulation with TNFa (Fig 2). The greatest release occurred dur-
ing the first 8 h of stimulation with PMA, whereas the time course 
of IL-1P - and TNFO'-stimulated IL-8 production was more pro-
tracted . 
Effect ofPKC Inhibitors on IL-8 Production Cytokine pro-
duction in various systems has been shown to be regulated by PKC 
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Figure 1. Effect ofPMA- or IL-1P stimulation on keratinocyte IL-8 
production. Human keratinocytes it! lIilro were stimulated with various 
concentrations of the phorbol ester PMA (A) or interleukin-lp (B) as 
described in Materials and Methods. After 18 h of incubation, the medium was 
collected and the IL-8 content determined by immunoassay as described. 
Each point represents the mean ± SD of four individual samples from a 
representative of at least two experiments. 
[23]. Therefore, in light of the possible relation between inhibition 
of PKC and IL-8 synthesis, several known PKC inhibitors were 
studied for their ability to modulate IL-1P- and PMA-stimulated 
IL-8 production. The PKC inhibitor staurosporine was found to be 
a very potent inhibitor ofIL-8 production in response to PMA (Fig 
3). The inhibition was dose dependent, with an ICso of approxi-
mately 1.0 nM. In contrast, staurosporine potentiated IL-lP-
stimulated IL-8 production in a somewhat dose-dependent manner 
(Fig 3). Similar results were observed with the selective PKC in-
hibitor chelerythril1e (data not shown). Thus, inhibition of PKC 
either inhibited or potentiated IL-8 synthesis depending on 
whether the keratinocytes were stimulated with PMA or IL-lp. 
Interestingly, staurosporine treatment resulted in a dose-dependent 
accumulation of IL-8 in the absence of stimulus, which was similar 
to its effect seen in IL-lp-stimulated cells although of lesser mag-
nitude (data not shown). 
Modulation ofIL-8 Production by Auranofin To determine 
whether the anti-inflammatory and immunomodulatory actions of 
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Figure 2. Timecourse oflL-S production. Human keratinocytes j " "jlra 
were stimulated with either PMA (0.1 tiM), IL-1P (1.0 ng/ ml), or TNFa 
(50 ng/ ml) and incubated for various lengths of time, as indicated. At the 
end of the incubation period, the medium was collected and the IL-8 content 
in each sample determined by immunoassay as described. Each point repre-
sents the mean ± SD of four individual samples from a representative of at 
least two experiments. 
auranofin might be related to cytokine production, the effect of 
auranofin, a known PKC inhibitor [27], on IL-8 production was 
investigated. Treatment of keratinocytes with auranofin just prior 
to stimulation with PMA resulted in a concentration-dependent 
inhibition ofIL-8 production measured by immunoassay (Fig 4) or 
Western blot (data not shown). The ICso for this inhibition was 
0.1 p.M. 
The effect of auranofin on IL-8 production was then investigated 
in cells stimulated with IL-lp. In contrast to the inhibitory action of 
auranofin on PMA-stimulated IL-8 production, a dose-dependent 
potentiation of IL-8 production was observed when keratinocytes 
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Figure 3. Effect of staurosporine on PMA- or IL-tp-stimulated IL-S 
production. Human keratinocytes i" vitro were treated with various con-
centrations of stau.rosporine and then stimulated with either PMA (0.1 J.lM) 
or IL-1P.(1.0 ng/ ml) as indicated. At the end of the 1S-h incubation period, 
the medIUm was collected and the IL-8 content in each sample determined ?y immunoassay, as de.scribed. Control levels ofIL-8 were 262 ± 34 pg/ ml 
m the case ofIL-1P - stImulated cells and 2506 ± 192 pg/ ml in PMA-stimu-
lated samples. Each point represents the mean ± SD of four individual sam-
ples from a representative of at least two experiments. 
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Figure 4. Effect of a.ura.nonn on PMA-stimulated IL-S production. 
Human keratlllocytes It I IlIlra were treated with various concentrations of 
auranofin and then stimulated with PMA (0.1 J.lM) as described in Materials 
arId Methods. After an 18-h incubation period, the medium was collected and 
the IL-S content determined by immunoassay. IL-S levels in control (no 
auranofin) cultures w~re 3262 ± 244 pg/ml. Each point represents the 
mean ± SD of four 1l1dlVlduai samples from a representative of four experi-
ments. 
were treated with auranonn prior to stimulation with IL-1P or 
TN Fa (Fig 5). IL-8 production was increased approximately three-
fold over controls by 1.0 p.M auranofin. This potentiation was con-
firmed by Western blot analysis (data not shown). Auranofin had no 
effect on IL-8 production in unstimulated keratinocytes (data not 
shown) . 
In an effort to further investigate auranofin's ability to modulate 
IL-8 production, compounds related to auranofin and another gold 
c.ompound were studied for their.ability to modulate IL-8 produc-
tl~n. In contrast to the modulatIOn of IL-8 production observed 
Wlt!l auranofin, a~'lOth~r gold-containing compound, sodium aur-
othlOmalate, was 111aCtlve (Fig 6). Sodium aurothiomalate has been 
reported to inhibit protei~ ki~lase C in Jurkat cells [32]. Its inability 
to modu!ate IL-8 production 111 human keratinocytes may be related 
to PKC Isozyme selectivity. Also, the two substructures of aurano-
fi~, triethylphosphine oxide and 2,3,4,6-tetra-O-acetyl-l-p-
thlOethyl-O-.glycoside (abbreviated triethylphosphine and glyco-
Side, respectively, in Fig 6), did not alter IL-8 production in 
response to either PMA or IL-1P stimulation (Fig 6). Thus, al-
t~ougl~ the. gold .portion of the molecule was necessary for this 
bIOlogIC aCtiVity, Its presence was not sufficient. 
E.ffect o~ T~eatInent Time The mechanism whereby protein 
kll1ase C millbitors modulate IL-8 synthesis was investigated fur-
ther by examining whether the time at which the cells were treated 
with auranofin relative to stimulation had any effect on its ability to 
modulate IL-8. production. In these studies kera tinocyte cultures 
~ere treated With auranofin either just prior to or 2 h after stimula-
tion. Auranofin had no effect on PMA-induced synthesis of IL-8 
when added 2 h after stimulation (Fig 7A). Therefore, auranofin 
was likely to be exerting its action at a point early in the synthesis of 
!L-8. In contrast, auranofin was found to potentiate IL-8 production 
m response to IL-lpwhether added just prior to or 2 h after stimula-
tion (Fig 7B). 
IL-8 Gene Expression in Cultured Keratinocytes Barker and 
co-workers have previously demonstrated rapid and dramatic IL-8 
mRNA production in keratinocytes stimulated with either IL-lp or 
PMA [7] . Peaks in the expression of IL-8 mRNA were reported at 
1 hand 3 h, respectively [7]. Therefore, these timepoints were cho-
sen to investigate the effect ofPKC inhibitors, including auranofin, 
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Figure 5. Effect of auranonn on IL-tft- and TNFa-stirnulated IL-S 
production. Human keratinocytes ill Ilitro were treated with various con-
centrations of auranofll1 and then stimulated with either IL-lft (1 ng/ ml) 
(A) or TNFa (50 ng/ ml) (B), as described in Materials and Methods. After 
an 18-h incubation period the medium was collected and the IL-8 content 
determined by immunoassay. IL-8 levels in control (no auranofin) cultures 
were 966 ± 21 pg/ ml in IL-l-stimulated samples and 821 ± 38 pg/ ml in 
TNF-stimulatecl samples. Each point represents the mean ± SD of four 
individual samples from a representative of at least two experiments. 
on IL-8 mRNA expression. IL-8 mRNA was not detectable in un-
stimulated keratinocytes, indicating that the gene is not constitu-
tively expressed in these cells (Fig 8). However, stimulation of 
keratinocytes with PMA (0.1 tiM) for 3 h resulted in th e expression 
of a 1.8-kb product corresponding to IL-8 mRNA (Table I, Fig 8) . 
IL-8 gene expression was 34% and 2% of control in samples treated 
with 0.05 tiM and 0.5 tiM auranofin, respectively (Table I, Fig 8). 
Consistent with its effects on IL-8 protein production, staurospor-
ine also inhibited IL-8 mRNA expression in PMA-stimulated kera-
tinocytes by 89% at a dose of 10 nM (Table I). 
Treatment of human keratinocytes with IL-lfi also increased the 
expression of IL-8 mRNA after 1 h of stimulation (Table I). The 
effects of auranofin and staurosporine observed with respect to IL-8 
protein levels were reflected in a potentiation of IL-8 gene expres-
sion measured 1 h after IL-1fi stimulation (Table I). Interleukin-8 
mRNA was 113% of control with 0.05 tiM auranofiJ1 and 325% of 
control at the O.S-tiM dose. Thus, the ability of PKC inhibitors to 
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Figure 6. Effect of the auranonn substructures and sodium aurothio-
malate on IL-S production. Human keratinocytes were treated with ci-
ther 3uranofin, its substructures, or sodium aurothiomalate and thcn stimu-
lated with PMA (0.1 pM) (A) or IL-lft (1.0 ng/ ml) (B) as described. The 
cultures were incubated for 18 h, after which the medium was collected and 
the levels ofIL-8 in the medium determined by immunoassay as described in 
Materials arid Methods . Each point represents the mean ± SD of four individ-
ual samples from a representative of at least two experiments. 
modulate IL-8 production appears to occur at the messenger RNA 
level. 
Co-stimulation ofKeratinocytes with IL-lfi and PMA Inter-
leukin-fi and PMA have been reported to work in concert in the 
stimulation of increased amounts of IL-2 produced from activated 
EL4-6.1 cells [23]. Similarly, these two stimuli were found to have a 
synergistic effect on the production of IL-8 from cultured keratino-
cytes (Fig 9) . Whereas both stimuli were effective by themselves, a 
combination of suboptimal concentrations of IL-1fi and PMA re-
sulted in approximately threefold as much IL-8 compared to stimu-
lation with PMA only and greater than the sum of the IL-8 pro-
duced in response to the two stimuli independently. 
Considering the magnitude of the increase in IL-8 production, 
the ability of auranofin to modulate IL-8 production under such 
co-stimulation conditions was investigated. As was seen in kerati-
VOL. 103, NO.4 OCTOBER 1994 
4000~--------------------------------------~ 
E 
Cl 
c.. 
A 
3000 
2000 
1000 
Before stimulation 
2h posl,slimulalion 
.01 .1 
Aurano!in 
10 
(~lM) 
4000 ~--------------------------------------~ 
E 3000 
Cl 
c.. 
CD 
c: 2000 
"" 
'" 4> 
1000 
8 
____ Before stimulation 
----.-- 2h post·stimulation 
.0 1 . 1 
Aurano!in (j.lM) 
10 
Figure 7. Effect of time of treatment on auranofin-mediated modu-
lation ofIL-S production. Human keratinocytes were cithcr stimulated 
with PMA (0.1 11M) (A) or IL-IP (1.0 ng/ ml) (B) in the presence of 
various concentrations of auranofin or stimulated and then incubated for 2 h 
at 37"C prior to treatment with auranofin. The culturcs wcre incubated for a 
total of 18 h. At the end of the incubation, the medium was collected and the 
IL-8 content determined by immunoassay. Each point represents thc 
mean ± SD of four individual samples from a representative of two experi-
ments. 
nocytes stimulated with PMA only, auranofin treatment resulted in 
a dose-dependent inhibition of IL-8 production (ICso = 0.3 J.lM) 
(Fig 10). 
DISCUSSION 
In terleukin-8 is a potent pro-inflammatory cytokine present in pro-
digious amounts in psoriatic lesions [6,16 - 18] . H ere it may con-
tribute to the neutrophil and T-Iymphocyte infiltration and kerati-
nocyte hyperproliferation characteristic of this disease. Although 
much is known about th e biologic properties ofIL-8, little is known 
concerning the regulation of its synthesis . As such, an understand-
ing of the mechanisms by which the synthesis of IL-8 can be regu-
lated would prove beneficial in the design of compounds to modu-
late IL-8 levels. These, in rum, may prove beneficial in the 
treatment of inflammatory diseases, including those of the skin . 
Consistent with previous findings [6,7]' human keratinocytes in 
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Figure S. Northern blot of auranofin-treated keratinocytes. Human 
kcratinocytes were treated with or without PMA (0.1 11M for 3 h) in the 
presence or absence of auranofin at the concentration indicated. At that time 
the RNA was extracted and the IL-8 mRNA subjected to Northern blot 
analysis, as described in Materials alld Methods. Shown is a representative of 
two experiments. 
culture were found to respond to stimulation w ith PMA or IL-l/3 by 
increasing IL-8 mRNA. Accompanying this increase in mRNA was 
an increase in IL-8 protein levels released into the medium. As such , 
these stimuli increased both the transcription and translation of the 
IL-8 gene product. Furthermore, the protein kinase C inhibitors 
staurosporine and auranofin were shown to differentially modulate 
both mRNA and protein levels depending on whether IL-8 synthe-
sis was stimulated with IL-l/3 or PMA. Although the correlation 
between IL-8 mRNA and protein levels clearly suggests that the 
effect takes place at the pretranslational level, it is not possible to 
conclude from these studies whether the modulation of IL-8 
mRNA levels is related to gene transcription or to the stabili ty of the 
mRNAs. 
In contrast to auranofin, staurosporine was found to upregulate 
the production of IL-8 in the absence of stimulation. A similar 
phenomenon has been reported by Cassatella and co-workers [33] in 
staurosporine-treated human neutrophils. These authors reported 
that staurosporine induced the expression of IL-8 mRNA as well as 
protein in the neutrophil. It is likely that staurosporine also upregu-
lates the expression ofIL-8 mRNA in human keratinocytes because 
no IL-8 mRNA is detectable in the absence of stimulation. Whether 
this modulation is related to inhibition of basal PKC activity is 
unclear at present. However, the ability of chelerythrine, a more 
selective PKC inhibitor [34], to exert a similar effect on the produc-
tion of IL-8 suggests that PKC is involved. Thus, inhibition of 
Table I. Effect of PKC Inhibitors on Interleukin-8 
mRNA Expression" 
Treatment 
PMA (0.1 JlM) 
Control 
Auranofin (0.05 11M) 
Auranofin (0.5 tlM) 
Contro l 
Staurosporine (10 nM) 
IL-IP (1.0 ng/mI) 
Control 
Auranofin (0.05 tlM) 
Auranohn (0.5 11M) 
Staurosporine (10 nM) 
Area Under Curvc 
6 .7 
2.3 
0.119 
3.3 
0.37 
0.43 
0.49 
1.4 
0.64 
Percent Control 
100 
34 
2 
100 
11.2 
100 
113 
325 
149 
" Human kcratillocytes were stimulated with either PMA (0.1 JLM for 3 h) or IL-IP 
(1.0 ng/ml for 1 h) in the presence or absence of the compounds indicated. At that time 
RNA was extracted and the IL-8 mRNA quantitated as described in Materials atld 
Met/rods. Each value represents a single determinarion from a representative of at least 
two experiments. 
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Figure 9. Effect of co-stimulation with PMA and IL-1P on keratino-
cyte IL-8 production. Human keratinocytes were stimulated with either 
IL- IP (0.5 ngj ml), PMA (0.01 J.lM), or a combination of the two stimuli 
and incubated for 18 hat 37"C. At the end of the incubation, the medium 
was collected and the IL-8 content determined by immunoassay_ Each point 
represents the mean ± SD of four individual samples from a representative 
of two experiments. 
staurosporine-sensitive enzymes is likely to be related to the increase 
of IL-8 gene exrression. 
The ability 0 PKC inhibitors to differentially modulate IL-1P-
and PMA-stimulated events has been reported in other systems. A 
similar phenomenon has been observed for the production of fruc-
tose 2,6-bisphosphate and PGE2 in cultured rheumatoid synovial 
cells and human dermal fibroblasts [24], as well as in the EL4-6.1 
thymoma cell line with respect to IL-2 and IL-4 synthesis [23]. 
Dornand et at [23] reported that nanomolar concentrations of staur-
osporine strongly potentiated the production of IL-2 or IL-4 when 
EL4-6 .1 cells were stimulated by IL-1. However, these investigators 
found that staurosporine dose-dependently inhibited the produc-
tion of IL-2 and IL-4 resulting from stimulation with PMA. A 
strong correlation between the effect of staurosporine on IL-2 and 
IL-4 protein secretion and mRNA levels was reported and inter-
preted as an indication that the differential regulation of cytokine 
production by inhibitors of PKC took place at the pretranslational 
level [23]. 
The 5
'
-flanking region of the IL-8 gene contains several potential 
binding sites for known nuclear factors whose activity may be regu-
lated by PKC. Included among these is NF-KB [1]. The PKC inhib-
itor H-7 has been reported to block NF-KB activation by the phor-
bol ester PMA [35], whereas activation ofNF-KB by IL-1/TNF was 
reported to be insensitive to PKC inhibitors [30,31] . Thus, PMA 
and IL-1/TNF may be exerting their effects through different sig-
nal transdution pathways wherein IL-l- and TNF-mediated re-
sponses may not directly involve the activation of PKC. However, 
PKC may playa role in the modulation of the IL-1/TNF signal 
transduction pathway_ Alternatively, one may speculate that iso-
zymes of PKC that are not sensitive to the commonly utilized in-
hibitors may playa role_ 
Additional evidence for the potential regulation by PKC at the 
pretranslationallevel has been observed in the activation ofNF-KB 
by TNFa. Hohmann and co-workers [36] have reported that HL-
60 and EI-4 cells incubated with TN Fa in the presence of stauro-
sporine showed a twofold increase in the levels of NF-KB activity 
compared to with TNFa alone. A similar phenomenon may also be 
involved in the potentiation of IL-l- mediated events by inhibitors 
of PKC. Interestingly, staurosporine has been reported to increase 
the activity of a set of novel serine/ threonine kinases [37]. As such, 
PKC may function as a negative regulator of other protein kinases. 
Thus, the synthesis of IL-8 in response to IL-1P, TNFa, or PMA 
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Figure 10. Effect of auranofin on co-stimulated IL-8 production. 
Human keratinocytes were stimulated with a combination of PMA 
(0.01 J.lM) and IL-1P (0.5 ngj ml) in the presence of various concentrations 
of auranofin. After an 18-h incubation the medium was collected and the 
IL-8 content determined by immunoassay. Each point represents the 
mean ± SD of four individual samples from a representative of two experi-
ments. 
may result from the activation of a responsive enhancer in the 5/-
flanking region of the IL-8 gene by a nuclear factor whose activity is 
regulated by a member of the protein kinase C family or another 
kinase, which in turn is regulated by PKC. Differential regulation 
of nuclear factor activity by PKC depending on the stimulus may 
underlie the results described herein. 
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